Ramosetron
drugOn this page
Also known as SID50112691Ramosetron (Hydrochloride)
Summary
Ramosetron (CHEMBL1643895) is an approved small molecule; indicated across 7 conditions including gastric neoplasm and neoplasm.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Small molecule
- Indications: 7 conditions
- Clinical trials: 42
- Chemistry: 279.34 Da · C17H17N3O
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL1643895 |
| Name | Ramosetron |
| Type | Small molecule |
| Max phase | 4 |
| FDA approved | no |
| PubChem CID | 108000 |
| Molecular formula | C17H17N3O |
| Molecular weight | 279.34 |
| InChIKey | NTHPAPBPFQJABD-LLVKDONJSA-N |
SMILES: CN1C=C(C2=CC=CC=C21)C(=O)[C@@H]3CCC4=C(C3)NC=N4
IUPAC name: (1-methylindol-3-yl)-[(5R)-4,5,6,7-tetrahydro-3H-benzimidazol-5-yl]methanone
Also known as: Ramosetron, SID50112691, RAMOSETRON, ramosetron, Ramosetron (Hydrochloride)
Parent form; salt/anhydrous children: CHEMBL3181841
Patent coverage: 2,534 distinct patent families (10,859 SureChEMBL compound mentions), from 3 matched compound structure(s). One matched structure accounts for 10,766 (99%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.
Targets
Targets
Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).
| Gene | Target | Action | pAffinity | Cancer dependency | UniProt |
|---|---|---|---|---|---|
| 5-HT3A | Antagonist | 10 |
Broader ChEMBL bioactivity targets: 9 (assay-derived). Sample: 5-hydroxytryptamine receptor 2B, Alpha-2A adrenergic receptor, 5-hydroxytryptamine receptor 3A, Alpha-2C adrenergic receptor, Alpha-2B adrenergic receptor, Sodium-dependent serotonin transporter, Kappa-type opioid receptor, Voltage-gated inwardly rectifying potassium channel KCNH2, Gamma-aminobutyric acid receptor subunit alpha-1.
Bioactivity
ChEMBL activities: 7 potent at pChembl ≥ 5 of 11 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):
| Target | pChembl | Type | Value | Unit | Activity ID |
|---|---|---|---|---|---|
| HTR3A | 10.22 | Ki | 0.06 | nM | CHEMBL_ACT_17684870 |
| HTR3A | 10.22 | Ki | 0.06 | nM | CHEMBL_ACT_5125664 |
| HTR3A | 9.4 | AC50 | 0.4 | nM | CHEMBL_ACT_25149342 |
| ADRA2B | 6.47 | AC50 | 340 | nM | CHEMBL_ACT_25143920 |
| SLC6A4 | 5.41 | AC50 | 3900 | nM | CHEMBL_ACT_25150548 |
| ADRA2A | 5.37 | AC50 | 4300 | nM | CHEMBL_ACT_25220100 |
| KCNH2 | 5.33 | AC50 | 4700 | nM | CHEMBL_ACT_25118175 |
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
7 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| gastric neoplasm | 3 | MONDO:0021085 | MONDO:0001056 |
| neoplasm | 3 | MONDO:0005070 | MONDO:0004992 |
5 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 42.
Phase distribution
| Phase | Trials |
|---|---|
| Not specified | 17 |
| PHASE4 | 13 |
| PHASE3 | 6 |
| PHASE2 | 4 |
| PHASE2/PHASE3 | 1 |
| EARLY_PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT07574320 | PHASE4 | NOT_YET_RECRUITING | Effect of Ramosetron in Patients With Diarrhea Predominant Irritable Bowel Syndrome |
| NCT00918411 | PHASE4 | COMPLETED | A Preliminary Study to Explore Clinical Endpoints in Patients (Male) With Diarrhea-predominant Irritable Bowel Syndrome |
| NCT01102491 | PHASE4 | COMPLETED | Additional Anti-emetic Effect of Ramosetron Prophylaxis After Total Knee Arthroplasty |
| NCT01225237 | PHASE4 | COMPLETED | A Study to Evaluate Efficacy of Ramosetron on Diarrhea-predominant Irritable Bowel Syndrome (IBS) in Male Patients |
| NCT01427127 | PHASE4 | UNKNOWN | Effect of Ramosetron on Bowel Motility After Colorectal Resection |
| NCT01637545 | PHASE4 | TERMINATED | Evaluation of Safety and Efficacy of Nasea(R)/Ramosetron Inj. in Patients Undergoing Facial Bone Fracture Operations |
| NCT02478645 | PHASE4 | COMPLETED | Dose-ranging Study of Ramosetron for the Prevention of Nausea and Vomiting After Gynecologic Laparoscopic Surgery |
| NCT02480088 | PHASE4 | COMPLETED | Comparison of Palonosetron and Ramosetron for Preventing Patient-controlled Analgesia Related Nausea and Vomiting Following Spine Surgery; Association With ABCB1 Polymorphism |
| NCT02532634 | PHASE4 | COMPLETED | Ramosetron, Aprepitant, and Dexamethasone Versus Palonosetron, Aprepitant, and Dexamethasone |
| NCT02803788 | PHASE4 | UNKNOWN | Post-operative Nausea Vomiting in Laparoscopic Cholecystectomy |
| NCT02849483 | PHASE4 | UNKNOWN | Effect of Ramosetron on Bowel Motility After Gynecological Surgery |
| NCT03278522 | PHASE4 | COMPLETED | Ramosetron Pre-treatment for PONV and QT Prolongation |
| NCT04297293 | PHASE4 | UNKNOWN | Ramosetron OD Tablet and Postdischarge Nausea and Vomiting |
| NCT00272285 | PHASE3 | COMPLETED | A Study of Ramosetron Plus DX, Dexamethasone, Compared to Granisetron Plus DX for the Prevention of Vomiting and Nausea |
| NCT00971399 | PHASE3 | COMPLETED | Ramosetron Versus Ondansetron for Radiotherapy Induced Nausea and Vomiting |
| NCT01536691 | PHASE3 | UNKNOWN | Ramosetron, Aprepitant and Dexamethasone Versus Ondansetron, Aprepitant and Dexamethasone |
| NCT02011659 | PHASE3 | UNKNOWN | Long Term Prevention of Nausea and Vomiting in Gynecologic Laparoscopy |
| NCT02444897 | PHASE3 | COMPLETED | The Comparison Between Epidural and Intravenous Patient-controlled Analgesia for Laparoscopic Gastrectomy |
| NCT02830906 | PHASE3 | COMPLETED | Effect of Ramosetron in Prevention of Intrathecal Morphine Induced Nausea and Vomiting |
| NCT06166615 | PHASE2/PHASE3 | UNKNOWN | The Safety and Efficacy of 5-HT3 Receptor Antagonist (Ramosetron) for the Treatment of Fecal Incontinence |
| NCT01012336 | PHASE2 | COMPLETED | Safety and Efficacy of Aprepitant, Ramosetron, and Dexamethasone for Chemotherapy-Induced Nausea and Vomiting in Patients With Ovarian Cancer Treated With Taxane/Carboplatin |
| NCT01046461 | PHASE2 | UNKNOWN | Ramosetron, Aprepitant and Dexamethasone (RAD) in Solid Cancer |
| NCT01788605 | PHASE2 | UNKNOWN | Efficacy Study of Ramosetron in the Setting of Hematopoietic Stem Cell Transplantation |
| NCT01806948 | PHASE2 | COMPLETED | Efficacy Study of Antiemetics to Reduce Postoperative Nausea and Vomiting |
| NCT02869984 | EARLY_PHASE1 | UNKNOWN | Clinical Trial Assessing 5-HT3 Receptor Antagonist (Ramosetron) for the Treatment of Anterior Resection Syndrome |
| NCT05577845 | Not specified | RECRUITING | 5-HT3 Receptor Antagonist (Ramosetron) vs Loperamide for the Treatment of Low Anterior Resection Syndrome(RALARS) |
| NCT01041183 | Not specified | UNKNOWN | The Effect of Oral and Intravenous Ramosetron During Laparoscopic Cholecystectomy |
| NCT01169805 | Not specified | COMPLETED | Prophylactic Effects of Ondansetron, Ramosetron, and Palonosetron on Patient-Controlled Analgesia Related Nausea and Vomiting After Urologic Laparoscopic Surgery |
| NCT01476280 | Not specified | COMPLETED | Palonosetron Versus Ramosetron for the Prevention of Postoperative Nausea and Vomiting |
| NCT01669213 | Not specified | UNKNOWN | Effects of Different Kinds, Different Doses of 5-HT3 Receptor Antagonists on Prevention of Hypotension |
| NCT01825733 | Not specified | COMPLETED | Comparison of Palonosetron and Ramosetron for Preventing Patient-controlled Analgesia Related Nausea and Vomiting Following Spine Surgery |
| NCT02076529 | Not specified | COMPLETED | Phamacokinetic and Pharmacodynamic Study of Ramosetron in Chemotherapy Induced Nasea and Vomiting |
| NCT02139241 | Not specified | COMPLETED | The Efficacy and Safety of Ramosetron in Patients Undergoing Off Pump Coronary Artery Bypass Surgery |
| NCT02416115 | Not specified | COMPLETED | Anti Emetic Efficacy of Combination of Ramosetron and Premixture of Naloxone With Patient-controlled Analgesia |
| NCT02597907 | Not specified | COMPLETED | Postoperative Nausea and Vomiting: Ramosetron Plus Aprepitant vs Palonosetron Plus Aprepitant |
| NCT02604797 | Not specified | UNKNOWN | Analgesia Effects of Nalbuphine vs Sulfentanil |
| NCT02612649 | Not specified | COMPLETED | Special Drug Use Surveillance of Irribow in Female Patients |
| NCT02617121 | Not specified | UNKNOWN | The Effects of Gabapentin and Ramosetron on Postoperative Nausea and Vomiting in Laparoscopic Gynecological Surgery |
| NCT02625181 | Not specified | COMPLETED | Real-time Decision Support for Postoperative Nausea and Vomiting (PONV) Prophylaxis |
| NCT03017222 | Not specified | COMPLETED | Therapeutic Efficacy of Ramosetron for Treatment of Established PONV After Laparoscopic Surgery |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
- Diseases: gastric neoplasm, neoplasm